We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
American Shared Hospital Services | AMEX:AMS | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.10 | 3.11% | 3.32 | 3.30 | 3.21 | 3.21 | 4,333 | 01:00:00 |
RNS Number:0888U Advanced Medical Solutions Grp PLC 12 January 2004 For Immediate Release Monday 12th January 2004 Advanced Medical Solutions Group plc ("AMS" or "the Company") Announces distribution deal for LiquiBandTM in Germany Winsford, UK: Advanced Medical Solutions, (AIM: AMS), the global woundcare technology company, today announces that it has entered into an agreement with Resorba Clinicare GmbH, a subsidiary of Resorba Wundversorgung GmbH & Co. KG ("Resorba") for distribution of its LiquiBandTM tissue adhesive range in Germany. LiquiBandTM is a medical adhesive that utilises super-glue technology for closing wounds for Accident & Emergency (A&E) and surgical applications as an alternative to stitching or stapling. AMS's MedLogic division is market leader for medical adhesives in the UK in the A&E arena and has recently launched LiquiBandTM Surgical, which is a product designed for closing surgical incisions in the operating theatre. This is the biggest market opportunity for this technology and it is estimated that 40% of the current $3 billion suture and staple market could move to medical glues in the future. Following the CE Mark approval for sale throughout Europe, MedLogic has been rolling this product out through its existing distributors and seeking new partners for key European markets such as Germany, where there is a good understanding of the surgical wound closure market, a presence in the operating theatre and a willingness to focus on new, innovative products. Based in N??renburg, Germany and with branch offices in Austria, Czech Republic and Russia, Resorba's 24 person sales team currently distributes wound closure products and surgical specialities for the operating theatre such as sutures, haemostats (collagen) and hernia meshes. Commenting on this announcement, Dr Don Evans, Chief Executive of AMS, stated: "I am delighted that we have found such a suitable partner for our medical adhesives in Germany. MedLogic's success in achieving market leadership in the UK A&E market, and our optimism for similar success in the operating theatre, is based on a highly focussed team being very close to end user customers and being seen as the experts in medical adhesives." "To build successful businesses in other markets requires distribution partners that are similarly knowledgeable and committed to delivering the enormous opportunity that this technology offers. I believe that Resorba offers that expertise and commitment to succeed in Germany." Mr. Claus Hiltner, Managing Director of Resorba, added: "We can see a significant interest in the benefits of using adhesives for closing surgical wounds, which we are in a strong position to exploit. MedLogic is an ideal partner for us with its technical back up and success in the UK, which is the largest and most competitive market in Europe for medical adhesives." "LiquiBandTM Surgical is a very exciting new product that can offer real benefits to surgeons, nursing staff and patients compared with conventional methods of wound closure." - ENDS - For further information, please contact: Advanced Medical Solutions Group plc Tel : +44 (0)1606 545508 Don Evans, Chief Executive Mary Tavener, Finance Director www.admedsol.com ------------------ Buchanan Communications Tel: +44 (0) 20 7466 5000 Mark Court, Mary-Jane Johnson Notes to Editors: Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market. Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative and technologically advanced products for woundcare and other medical applications. In-house natural and synthetic polymer technology is used to provide advanced wound dressings based on the moist healing principle. AMS's resources ensure a unique position as a vertically integrated 'one stop shop' to provide all categories of moist wound healing products. The Company has the capability to move from product design and development through to production and delivery ready for distribution into customer markets. The acquisition of MedLogic in 2002 has brought AMS products and technology in cyanoacrylate based tissue adhesives and sealants sold direct to hospitals or through distributors. AMS's technology and products currently serve the majority of the key global markets with strategic partners including 3M, Novartis, Johnson & Johnson, Molnlycke Healthcare, Coloplast, Smith + Nephew and Beiersdorf. This information is provided by RNS The company news service from the London Stock Exchange END MSCGGGGMRLMGDZM
1 Year American Shared Hospital... Chart |
1 Month American Shared Hospital... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions